209 related articles for article (PubMed ID: 37645436)
1. Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy.
Kagiava A; Karaiskos C; Lapathitis G; Heslegrave A; Sargiannidou I; Zetterberg H; Bosch A; Kleopa KA
Mol Ther Methods Clin Dev; 2023 Sep; 30():377-393. PubMed ID: 37645436
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal gene therapy in mouse models expressing CMT1X mutations.
Kagiava A; Karaiskos C; Richter J; Tryfonos C; Lapathitis G; Sargiannidou I; Christodoulou C; Kleopa KA
Hum Mol Genet; 2018 Apr; 27(8):1460-1473. PubMed ID: 29462293
[TBL] [Abstract][Full Text] [Related]
3. Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X.
Kyriakoudi S; Sargiannidou I; Kagiava A; Olympiou M; Kleopa KA
Hum Mol Genet; 2017 May; 26(9):1622-1633. PubMed ID: 28334782
[TBL] [Abstract][Full Text] [Related]
4. AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy.
Kagiava A; Karaiskos C; Richter J; Tryfonos C; Jennings MJ; Heslegrave AJ; Sargiannidou I; Stavrou M; Zetterberg H; Reilly MM; Christodoulou C; Horvath R; Kleopa KA
Gene Ther; 2021 Nov; 28(10-11):659-675. PubMed ID: 33692503
[TBL] [Abstract][Full Text] [Related]
5. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X.
Kagiava A; Richter J; Tryfonos C; Karaiskos C; Heslegrave AJ; Sargiannidou I; Rossor AM; Zetterberg H; Reilly MM; Christodoulou C; Kleopa KA
Hum Mol Genet; 2019 Nov; 28(21):3528-3542. PubMed ID: 31411673
[TBL] [Abstract][Full Text] [Related]
6. Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease.
Sargiannidou I; Kagiava A; Bashiardes S; Richter J; Christodoulou C; Scherer SS; Kleopa KA
Ann Neurol; 2015 Aug; 78(2):303-16. PubMed ID: 26010264
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling studies in regenerating nerves in a mouse model for CMT1X: uninjured Cx32-knockout peripheral nerves display expression profile of injured wild type nerves.
Freidin M; Asche-Godin S; Abrams CK
Exp Neurol; 2015 Jan; 263():339-49. PubMed ID: 25447941
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy.
Kagiava A; Sargiannidou I; Theophilidis G; Karaiskos C; Richter J; Bashiardes S; Schiza N; Nearchou M; Christodoulou C; Scherer SS; Kleopa KA
Proc Natl Acad Sci U S A; 2016 Apr; 113(17):E2421-9. PubMed ID: 27035961
[TBL] [Abstract][Full Text] [Related]
9. Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice.
Scherer SS; Xu YT; Messing A; Willecke K; Fischbeck KH; Jeng LJ
J Neurosci; 2005 Feb; 25(6):1550-9. PubMed ID: 15703409
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetics of X-linked Charcot-Marie-Tooth disease.
Kleopa KA; Scherer SS
Neuromolecular Med; 2006; 8(1-2):107-22. PubMed ID: 16775370
[TBL] [Abstract][Full Text] [Related]
11. Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy.
Schiza N; Georgiou E; Kagiava A; Médard JJ; Richter J; Tryfonos C; Sargiannidou I; Heslegrave AJ; Rossor AM; Zetterberg H; Reilly MM; Christodoulou C; Chrast R; Kleopa KA
Brain; 2019 May; 142(5):1227-1241. PubMed ID: 30907403
[TBL] [Abstract][Full Text] [Related]
12. Genetic epidemiology of Charcot-Marie-Tooth disease.
Braathen GJ
Acta Neurol Scand Suppl; 2012; (193):iv-22. PubMed ID: 23106488
[TBL] [Abstract][Full Text] [Related]
13. Two new mouse models of Gjb1-associated Charcot-Marie-Tooth disease type 1X.
Tadenev ALD; Hatton CL; Pattavina B; Mullins T; Schneider R; Bogdanik LP; Burgess RW
J Peripher Nerv Syst; 2023 Sep; 28(3):317-328. PubMed ID: 37551045
[TBL] [Abstract][Full Text] [Related]
14. Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease.
Olympiou M; Sargiannidou I; Markoullis K; Karaiskos C; Kagiava A; Kyriakoudi S; Abrams CK; Kleopa KA
Acta Neuropathol Commun; 2016 Sep; 4(1):95. PubMed ID: 27585976
[TBL] [Abstract][Full Text] [Related]
15. What's the Function of Connexin 32 in the Peripheral Nervous System?
Bortolozzi M
Front Mol Neurosci; 2018; 11():227. PubMed ID: 30042657
[TBL] [Abstract][Full Text] [Related]
16. Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie Tooth neuropathy.
Vavlitou N; Sargiannidou I; Markoullis K; Kyriacou K; Scherer SS; Kleopa KA
J Neuropathol Exp Neurol; 2010 Sep; 69(9):945-58. PubMed ID: 20720503
[TBL] [Abstract][Full Text] [Related]
17. Connexins, gap junctions and peripheral neuropathy.
Kleopa KA; Sargiannidou I
Neurosci Lett; 2015 Jun; 596():27-32. PubMed ID: 25449862
[TBL] [Abstract][Full Text] [Related]
18. Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients.
Hattori N; Yamamoto M; Yoshihara T; Koike H; Nakagawa M; Yoshikawa H; Ohnishi A; Hayasaka K; Onodera O; Baba M; Yasuda H; Saito T; Nakashima K; Kira J; Kaji R; Oka N; Sobue G;
Brain; 2003 Jan; 126(Pt 1):134-51. PubMed ID: 12477701
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and cellular expression of two novel connexin32 mutations causing CMT1X.
Kleopa KA; Zamba-Papanicolaou E; Alevra X; Nicolaou P; Georgiou DM; Hadjisavvas A; Kyriakides T; Christodoulou K
Neurology; 2006 Feb; 66(3):396-402. PubMed ID: 16476939
[TBL] [Abstract][Full Text] [Related]
20. How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease?
Kleopa KA; Abrams CK; Scherer SS
Brain Res; 2012 Dec; 1487():198-205. PubMed ID: 22771394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
